Kairos Pharma Outlines 2025 Plans and Exciting Developments

Exciting Developments from Kairos Pharma

Kairos Pharma Ltd. (NYSE American: KAPA), a pioneering clinical-stage biopharmaceutical company, is dedicated to developing innovative therapies aimed at overcoming cancer drug resistance and immune suppression. In a recent communication to stakeholders, the management team provided an insightful update on the company's journey, outlining key accomplishments from 2024 and laying out a strategic outlook for 2025.

Key Accomplishments of 2024

Throughout 2024, Kairos Pharma focused on building a robust foundation grounded in breakthrough science. This strategy enabled the company to bridge the gap between cutting-edge research and practical, impactful therapeutics. Notable achievements include:

• Successful completion of the Initial Public Offering, marking a significant listing of common stock on the NYSE American.
• Collaboration with PreCheck Health Services to enhance a biomarker panel for identifying patients likely to respond to ENV105.
• Collaborative efforts with the City of Hope Cancer Center as part of the Phase 2 clinical trial of ENV 105 for treating prostate cancer.
• Administering the first dose to a patient in the combination therapy trial of ENV105 and Osimertinib for EGFR-driven lung cancer.
• Active participation and presentations at numerous investor conferences to build awareness within the investment community.
• Initiating research coverage through renowned healthcare analysts in the industry.
• Securing $3.5 million in gross proceeds from a PIPE transaction to fuel ongoing clinical trials and enhance preclinical asset development.
• Strengthening patent protections across domestic and international markets to safeguard valuable technologies.

Strategic Vision for 2025

Looking ahead to 2025, Kairos Pharma is excited about upcoming milestones that are poised to significantly advance its mission. The planned initiatives include:

• Continuing the execution of the Phase 2 randomized clinical trial of ENV 105 for prostate cancer.
• Advancing the Phase 1 trial focusing on non-small cell lung cancer.
• Providing updates on safety and interim efficacy data, with initial insights expected in the first half of 2025 for prostate cancer.
• Presenting pivotal data at national scientific events that will showcase advancements in research.
• Conducting Pre-IND studies for KROS 101, with findings anticipated for publication.
• Beginning discussions for potential partnerships to further drive research initiatives.

Commitment to Patients and Research

Kairos Pharma remains dedicated to its mission of transforming the landscape of cancer treatment. The company believes in the significant potential of its therapies, which are based on innovative scientific principles, to create lasting change in the treatment of neoplastic disorders. With a strong focus on the needs of patients and the commitment of its partners and shareholders, Kairos Pharma aims to expand its scientific endeavors while maximizing shareholder value both now and in the future.

About Kairos Pharma Ltd.

Headquartered in Los Angeles, Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics. The company leverages advancements in structural biology to tackle drug resistance and immune suppression encountered in cancer treatments. Its lead therapy, ENV105, specifically targets CD105, a protein linked to resistance against existing cancer therapies. As ENV105 continues through clinical trials for prostate and lung cancer, Kairos Pharma is committed to addressing the unmet medical needs affecting countless individuals.

Frequently Asked Questions

What are the main highlights of Kairos Pharma's 2024 achievements?

Kairos Pharma's major highlights include a successful IPO, partnerships to develop new biomarkers, and the commencement of key clinical trials for its lead drug, ENV105.

What is ENV105 and its relevance in cancer treatment?

ENV105 is an antibody therapy developed by Kairos Pharma that targets CD105 to combat drug resistance in various forms of cancer, including lung and prostate cancer.

What are the goals for Kairos Pharma in 2025?

In 2025, Kairos Pharma aims to advance its clinical trials, present at scientific meetings, and initiate crucial partnership discussions.

How does Kairos Pharma support cancer patients?

Kairos Pharma is dedicated to developing therapies that address significant medical needs and improve treatment outcomes for patients suffering from cancer.

Who is the CEO of Kairos Pharma Ltd.?

The CEO of Kairos Pharma Ltd. is John Yu, M.D., who oversees the company’s strategic direction and clinical development initiatives.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. If any of the material offered here is inaccurate, please contact us for corrections.